edp 305
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2016 (NCT02918929)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bile acid receptor FXRAGONIST
NR1H4 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- edp 305
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03213145 | Phase 1 | Jul 11, 2017 | Enanta Pharmaceuticals |
| NCT03207425 | Phase 1 | Jun 14, 2017 | Enanta Pharmaceuticals |
| NCT02918929 | Phase 1 | Sep 1, 2016 | Enanta Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals | For profit | 3 | 3 | 1 | 2016 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1